vs
DOMO, INC.（DOMO）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是DOMO, INC.的1.8倍（$140.6M vs $79.4M），VERACYTE, INC.净利率更高（29.3% vs -13.1%，领先42.3%），VERACYTE, INC.同比增速更快（18.5% vs -0.5%），VERACYTE, INC.自由现金流更多（$48.8M vs $1.1M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -0.5%）
Domo股份有限公司是总部设在美国犹他州美国福克的美国云软件企业，主营人工智能、商业智能与数据可视化业务，属于SaaS（软件即服务）企业，核心产品可帮助企业各层级决策者在极少IT介入的情况下，实时获取业务数据，支撑决策开展。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
DOMO vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.8倍
$79.4M
营收增速更快
VCYT
高出19.0%
-0.5%
净利率更高
VCYT
高出42.3%
-13.1%
自由现金流更多
VCYT
多$47.7M
$1.1M
两年增速更快
VCYT
近两年复合增速
-0.5%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $140.6M |
| 净利润 | $-10.4M | $41.1M |
| 毛利率 | 74.2% | 72.5% |
| 营业利润率 | -8.7% | 26.4% |
| 净利率 | -13.1% | 29.3% |
| 营收同比 | -0.5% | 18.5% |
| 净利润同比 | 44.6% | 704.8% |
| 每股收益（稀释后） | $-0.25 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMOVCYT
| Q4 25 | $79.4M | $140.6M | ||
| Q3 25 | $79.7M | $131.9M | ||
| Q2 25 | $80.1M | $130.2M | ||
| Q1 25 | $78.8M | $114.5M | ||
| Q4 24 | $79.8M | $118.6M | ||
| Q3 24 | $78.4M | $115.9M | ||
| Q2 24 | $80.1M | $114.4M | ||
| Q1 24 | $80.2M | $96.8M |
净利润DOMOVCYT
| Q4 25 | $-10.4M | $41.1M | ||
| Q3 25 | $-22.9M | $19.1M | ||
| Q2 25 | $-18.1M | $-980.0K | ||
| Q1 25 | $-17.7M | $7.0M | ||
| Q4 24 | $-18.8M | $5.1M | ||
| Q3 24 | $-19.5M | $15.2M | ||
| Q2 24 | $-26.0M | $5.7M | ||
| Q1 24 | $-18.7M | $-1.9M |
毛利率DOMOVCYT
| Q4 25 | 74.2% | 72.5% | ||
| Q3 25 | 74.8% | 69.2% | ||
| Q2 25 | 74.2% | 69.0% | ||
| Q1 25 | 74.4% | 69.5% | ||
| Q4 24 | 75.0% | 66.4% | ||
| Q3 24 | 74.3% | 68.2% | ||
| Q2 24 | 74.1% | 68.1% | ||
| Q1 24 | 76.3% | 64.5% |
营业利润率DOMOVCYT
| Q4 25 | -8.7% | 26.4% | ||
| Q3 25 | -9.1% | 17.4% | ||
| Q2 25 | -17.9% | -4.0% | ||
| Q1 25 | -15.6% | 2.5% | ||
| Q4 24 | -13.9% | 3.5% | ||
| Q3 24 | -18.5% | 10.4% | ||
| Q2 24 | -26.8% | 4.0% | ||
| Q1 24 | -16.6% | -4.8% |
净利率DOMOVCYT
| Q4 25 | -13.1% | 29.3% | ||
| Q3 25 | -28.8% | 14.5% | ||
| Q2 25 | -22.5% | -0.8% | ||
| Q1 25 | -22.4% | 6.2% | ||
| Q4 24 | -23.5% | 4.3% | ||
| Q3 24 | -24.9% | 13.1% | ||
| Q2 24 | -32.5% | 5.0% | ||
| Q1 24 | -23.3% | -1.9% |
每股收益（稀释后）DOMOVCYT
| Q4 25 | $-0.25 | $0.50 | ||
| Q3 25 | $-0.56 | $0.24 | ||
| Q2 25 | $-0.45 | $-0.01 | ||
| Q1 25 | $-0.45 | $0.09 | ||
| Q4 24 | $-0.48 | $0.07 | ||
| Q3 24 | $-0.51 | $0.19 | ||
| Q2 24 | $-0.69 | $0.07 | ||
| Q1 24 | $-0.51 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $362.6M |
| 总债务越低越好 | $124.2M | — |
| 股东权益账面价值 | $-191.9M | $1.3B |
| 总资产 | $201.6M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOMOVCYT
| Q4 25 | — | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | $47.2M | $219.5M | ||
| Q1 25 | $45.3M | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | $61.2M | $235.9M | ||
| Q1 24 | $60.9M | $209.2M |
总债务DOMOVCYT
| Q4 25 | $124.2M | — | ||
| Q3 25 | $121.9M | — | ||
| Q2 25 | $119.7M | — | ||
| Q1 25 | $117.7M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $115.2M | — | ||
| Q2 24 | $114.1M | — | ||
| Q1 24 | $113.5M | — |
股东权益DOMOVCYT
| Q4 25 | $-191.9M | $1.3B | ||
| Q3 25 | $-191.5M | $1.3B | ||
| Q2 25 | $-178.7M | $1.2B | ||
| Q1 25 | $-177.2M | $1.2B | ||
| Q4 24 | $-171.2M | $1.2B | ||
| Q3 24 | $-166.4M | $1.2B | ||
| Q2 24 | $-163.5M | $1.1B | ||
| Q1 24 | $-153.5M | $1.1B |
总资产DOMOVCYT
| Q4 25 | $201.6M | $1.4B | ||
| Q3 25 | $195.7M | $1.4B | ||
| Q2 25 | $189.7M | $1.3B | ||
| Q1 25 | $214.3M | $1.3B | ||
| Q4 24 | $190.2M | $1.3B | ||
| Q3 24 | $197.8M | $1.3B | ||
| Q2 24 | $204.4M | $1.2B | ||
| Q1 24 | $225.7M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.4M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $1.1M | $48.8M |
| 自由现金流率自由现金流/营收 | 1.4% | 34.7% |
| 资本支出强度资本支出/营收 | 2.9% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $9.9M | $126.6M |
8季度趋势，按日历期对齐
经营现金流DOMOVCYT
| Q4 25 | $3.4M | $52.6M | ||
| Q3 25 | $3.4M | $44.8M | ||
| Q2 25 | $4.0M | $33.6M | ||
| Q1 25 | $8.9M | $5.4M | ||
| Q4 24 | $-13.7M | $24.5M | ||
| Q3 24 | $-6.2M | $30.0M | ||
| Q2 24 | $1.9M | $29.6M | ||
| Q1 24 | $5.4M | $-9.0M |
自由现金流DOMOVCYT
| Q4 25 | $1.1M | $48.8M | ||
| Q3 25 | $1.0M | $42.0M | ||
| Q2 25 | $1.0M | $32.3M | ||
| Q1 25 | $6.7M | $3.5M | ||
| Q4 24 | $-16.2M | $20.4M | ||
| Q3 24 | $-8.4M | $27.7M | ||
| Q2 24 | $-625.0K | $26.8M | ||
| Q1 24 | $2.9M | $-11.1M |
自由现金流率DOMOVCYT
| Q4 25 | 1.4% | 34.7% | ||
| Q3 25 | 1.3% | 31.8% | ||
| Q2 25 | 1.3% | 24.8% | ||
| Q1 25 | 8.5% | 3.1% | ||
| Q4 24 | -20.3% | 17.2% | ||
| Q3 24 | -10.7% | 23.9% | ||
| Q2 24 | -0.8% | 23.4% | ||
| Q1 24 | 3.6% | -11.5% |
资本支出强度DOMOVCYT
| Q4 25 | 2.9% | 2.7% | ||
| Q3 25 | 2.9% | 2.1% | ||
| Q2 25 | 3.7% | 1.0% | ||
| Q1 25 | 2.8% | 1.6% | ||
| Q4 24 | 3.2% | 3.5% | ||
| Q3 24 | 2.8% | 1.9% | ||
| Q2 24 | 3.2% | 2.4% | ||
| Q1 24 | 3.1% | 2.2% |
现金转化率DOMOVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
